Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Given Opella’s significant economic contribution to France, Sanofi’s divestment prompted concerns in the country about the potential loss of a strategic asset to a US company. The Bpifrance ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

France, Sanofi (NASDAQ:SNY) is a global healthcare company providing therapeutic solutions for diabetes, cardiovascular diseases, rare diseases, oncology, and immunology, alongside established ...

France's rising debt, fiscal deficits, and sluggish GDP growth weigh on EWQ ETF performance. See why we rate the ETF a sell ...

"Its history includes some of the major scientific advances of the nineteenth and twentieth centuries…" On 18th May 1999, Sanofi and Synthélabo officially came together in Paris, France to form ...

Tarrytown, N.Y., biotechnology company Regeneron created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement, while Sanofi markets the product ...